The new status, valid for one year and renewable annually, enables German hospitals to negotiate reimbursement coverage for Neovasc Reducer therapy under the country's health insurance system.
•CE-Mark'd Reducer is used to treat refractory angina, a painful condition caused by inadequate blood flow to the heart despite standard revascularization or cardiac drug treatments. Neovasc (NASDAQ:NVCN)
0 Comments
|
Mesothelioma BlogArchives
September 2020
Categories
All
|